Cargando…

Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis

Objective: This study aimed to compare the safety profile of tyrosine kinase inhibitors (TKIs) approved for use as monotherapy or combination therapy for the first-line treatment of adult patients with metastatic clear cell renal cell carcinoma (RCC). Methods: A systematic review with frequentist ne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krawczyk, Kinga, Śladowska, Katarzyna, Holko, Przemysław, Kawalec, Paweł
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512702/ https://www.ncbi.nlm.nih.gov/pubmed/37745049 http://dx.doi.org/10.3389/fphar.2023.1223929

Ejemplares similares

Impact of Biologic Treatment of Crohn’s Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland
por: Holko, Przemysław, et al.
Publicado: (2018)

Cost-utility analysis of Ruconest(®) (conestat alfa) compared to Berinert(®) P (human C1 esterase inhibitor) in the treatment of acute, life-threatening angioedema attacks in patients with hereditary angioedema
por: Kawalec, Paweł, et al.
Publicado: (2013)

A Comment on Craig et al.: ‘‘Retigabine for the Adjunctive Treatment of Adults with Partial-Onset Seizures in Epilepsy with and without Secondary Generalization: A NICE Single Technology Appraisal’’
por: Holko, Przemysław, et al.
Publicado: (2013)

Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2018)

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2012)

Renal adverse reactions of tyrosine kinase inhibitors in the treatment of tumours: A Bayesian network meta-analysis
por: Xiong, Ying, et al.
Publicado: (2022)

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab
por: Niewada, Maciej, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
por: Holko, Przemysław, et al.
Publicado: (2018)

Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR(®) TS
por: Holko, Przemyslaw, et al.
Publicado: (2011)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Health-Related Quality of Life Impairment and Indirect Cost of Crohn’s Disease: A Self-Report Study in Poland
por: Holko, Przemysław, et al.
Publicado: (2016)

Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis
por: Mulas, Olga, et al.
Publicado: (2021)

Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: a pharmacovigilance disproportionality analysis
por: Xue, Yifei, et al.
Publicado: (2023)

Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors
por: Centanni, Maddalena, et al.
Publicado: (2020)

Predicting individual-specific cardiotoxicity responses induced by tyrosine kinase inhibitors
por: Shim, Jaehee V., et al.
Publicado: (2023)

The Potential of Scopolamine as an Antidepressant in Major Depressive Disorder: A Systematic Review of Randomized Controlled Trials
por: Moćko, Paweł, et al.
Publicado: (2023)

Analysis of intracellular tyrosine phosphorylation in circulating neutrophils as a rapid assay for the in vivo effect of oral tyrosine kinase inhibitors
por: Futosi, Krisztina, et al.
Publicado: (2023)

Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis
por: Kawalec, P., et al.
Publicado: (2017)

Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis
por: Paech, Franziska, et al.
Publicado: (2017)

Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential
por: Rivera-Torres, José, et al.
Publicado: (2019)

The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae
por: Wang, Kun, et al.
Publicado: (2021)

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
por: Singh, Desh Deepak, et al.
Publicado: (2022)

Icotinib derivatives as tyrosine kinase inhibitors with anti-esophageal squamous carcinoma activity
por: Chen, Xiaojie, et al.
Publicado: (2022)

Indirect Costs of Inflammatory Bowel Diseases: A Comparison of Patient-Reported Outcomes Across 12 European Countries
por: Holko, Przemysław, et al.
Publicado: (2022)

Out-of-pocket expenses of patients with inflammatory bowel disease: a comparison of patient-reported outcomes across 12 European countries
por: Holko, Przemysław, et al.
Publicado: (2022)

Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis
por: Manz, Kirsi M., et al.
Publicado: (2019)

Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study
por: Liu, Yihan, et al.
Publicado: (2022)

Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection
por: Climent, Núria, et al.
Publicado: (2019)

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib
por: Lu, Ziwen, et al.
Publicado: (2022)

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib
por: Kawalec, Paweł, et al.
Publicado: (2017)

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
por: Kawalec, Paweł, et al.
Publicado: (2019)

Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
por: Kaehler, Meike, et al.
Publicado: (2021)

Novel biomarkers used for early diagnosis and tyrosine kinase inhibitors as targeted therapies in colorectal cancer
por: Jiang, Huafeng, et al.
Publicado: (2023)

Downregulation of miR-146a Contributes to Cardiac Dysfunction Induced by the Tyrosine Kinase Inhibitor Sunitinib
por: Shen, Li, et al.
Publicado: (2019)

Design, synthesis and evaluation of a series of potential prodrugs of a Bruton’s tyrosine kinase (BTK) inhibitor
por: Xiao, Zhou-Peng, et al.
Publicado: (2023)

Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients
por: Semeniuk-Wojtaś, Aleksandra, et al.
Publicado: (2016)

Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
por: Wu, Jialu, et al.
Publicado: (2020)

Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis
por: Wei, Qige, et al.
Publicado: (2023)

The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma
por: Buti, Sebastiano, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b8b4h39ed96e15f6n112kk4a1v